RemeGen Acquires Additional RMB370.00 Million Principal-Guaranteed Wealth Products from SPDB, Raising 12-Month Total to RMB670.00 Million

Bulletin Express10-14 17:41

RemeGen Co., Ltd. (RemeGen) disclosed that on 14 October 2026 it entered into two new wealth-management agreements with Shanghai Pudong Development Bank’s Yantai Branch (SPDB Yantai). The company will deploy RMB70.00 million and RMB300.00 million of idle self-owned funds into principal-guaranteed, floating-return structured deposits—products “Liduoduo Corporate Stable Profit 99JG4360” (69-day tenor, maturity 23 December 2026) and “Liduoduo Corporate Stable Profit 99JG4361” (30-day tenor, maturity 13 November 2026), respectively. Both instruments are linked to the EUR-USD exchange rate and offer tiered annualised yields of 0.70%, 1.75% or 1.95%, with SPDB retaining early-termination rights.

These purchases follow earlier transactions with the same bank: RMB200.00 million on 6 May 2026 and RMB100.00 million on 13 May 2026. Aggregated, RemeGen has now committed RMB670.00 million to SPDB wealth-management products within the past 12 months.

RemeGen’s board had previously authorised utilisation of up to RMB2.50 billion in idle self-owned funds and up to RMB80.00 million of idle A-share proceeds for cash management, a resolution passed at the board’s 36th meeting on 27 March 2026.

Under Hong Kong Listing Rule 14.22, the four SPDB agreements are aggregated as a single transaction. With at least one applicable percentage ratio exceeding 5% but all below 25%, the combined purchase is classified as a discloseable transaction under Chapter 14, triggering mandatory reporting and announcement requirements.

Management stated that deploying idle funds into low-to-medium risk, principal-protected products with yields above comparable term deposits enhances capital efficiency while maintaining controlled risk. The agreements were negotiated on an arm’s-length basis, and the board deems the terms fair and in the interests of shareholders.

RemeGen remains a commercial-stage biopharmaceutical company focused on innovative biologics for autoimmune, oncology and ophthalmic diseases, with H-shares listed on the Hong Kong Stock Exchange and A-shares on the Shanghai STAR Market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment